Wegovy and Ozempic: What is important about GLP-1 medications from a naturopathic perspective
- Nadia Licci
- Mar 11
- 5 min read
GLP-1 medications like Wegovy and Ozempic have changed the way people lose weight. Their effectiveness is real, and the studies are conclusive. At the same time, these drugs deeply affect hormonal and metabolic processes.
From a naturopathic perspective, the question is not whether these medications work, but rather how the body can be supported during and after treatment so that weight loss does not come at the expense of muscle mass, nutrient balance, or long-term regulatory mechanisms.
What are Wegovy and Ozempic?
Both medications contain the active ingredient semaglutide, a so-called GLP-1 receptor agonist. GLP-1 is a naturally occurring gut hormone that is released after eating and performs several functions:
It promotes insulin secretion in cases of elevated blood sugar, inhibits glucagon release from the liver, delays gastric emptying, and suppresses the feeling of hunger via the central nervous system.
Ozempic is originally approved for the treatment of type 2 diabetes. Wegovy contains the same active ingredient but is specifically designed for weight loss and is available in higher doses.
The effect is based on the fact that natural GLP-1 is broken down in the body within a few minutes. Semaglutide is modified so that it has a significantly longer duration of action and can be injected once a week.
The effect: Weight loss through a mechanism
Studies show average weight loss of ten to fifteen percent of body weight over a year. Some people lose more, others less. The effect is not due to fat burning, but to reduced appetite and prolonged satiety.
This leads to a significantly reduced calorie intake. At the same time, blood sugar levels stabilize, and blood pressure and blood lipid levels can improve. In people with type 2 diabetes, long-term blood sugar levels decrease measurably.
This effect is real. But it deeply interferes with metabolic processes that go beyond weight.
The problem: muscle loss without countermeasures
Every form of weight loss is accompanied by a loss of lean body mass. This is physiologically normal. Studies show that with conventional weight loss, approximately 20 to 30 percent of the lost weight consists of muscle mass.
With GLP-1 therapies, this proportion is in the same range. This means that someone who loses fifteen kilograms will lose an average of three to five kilograms of muscle mass.
This becomes problematic if no countermeasures are taken. Less muscle mass means a lower basal metabolic rate, reduced physical performance, and a higher risk of metabolic imbalances after discontinuing therapy.
Current research suggests that GLP-1 agonists may activate signaling pathways that promote muscle breakdown. These mechanisms are still being investigated. Regardless, one thing is clear: without targeted strength training and sufficient protein intake, muscle loss remains a major problem.
Nutrition during GLP-1 therapy: Less is not automatically better
Many people taking semaglutide eat significantly less. This is intentional. At the same time, protein intake often decreases as well, because appetite is generally suppressed.
Studies recommend a daily protein intake of 1.2 to 2.0 grams per kilogram of body weight to prevent muscle loss. For someone weighing 80 kilograms, this means 130 to 175 grams of protein daily.
Without conscious control, this amount is often not reached during GLP-1 therapy. As a result, the body breaks down muscle protein to provide amino acids.
At the same time, micronutrients can be deficient. Vitamin B12, iron, zinc, magnesium, and vitamin D are often insufficiently supplied when food intake is reduced. These nutrients are not only important for energy and the immune system, but also for muscle maintenance and hormonal regulation.
Exercise: Strength training is not an option, but a necessity
Without strength training, the body loses a disproportionate amount of muscle mass during GLP-1 therapy. Studies show that regular resistance training can significantly reduce this loss.
Two to three training sessions per week focusing on the large muscle groups are sufficient to maintain muscle mass. This isn't about high-performance sports, but rather about targeted training stimuli that signal to the body: This structure is needed.
Additionally, moderate exercise such as walking or cycling supports insulin sensitivity and promotes recovery. Intense endurance exercise, on the other hand, can be counterproductive if the body is already operating in a calorie deficit.
Side effects: nausea, constipation and more
The most common side effects of Wegovy and Ozempic affect the gastrointestinal tract. Nausea, bloating, constipation, or diarrhea occur particularly at the beginning of therapy.
These symptoms often subside after a few weeks, once the body has adjusted to the medication. The gradual increase in dosage is intended to facilitate precisely this.
Less common, but more relevant, are potential effects on the pancreas. Pancreatitis has been reported in isolated cases. The risk of gallstones may also increase, as rapid weight loss alters bile flow.
Long-term data is still lacking. Most studies run for one to two years. What happens after five or ten years of therapy is still unclear.
After stopping: The yo-yo effect is real
When semaglutide is discontinued, appetite returns. Studies show that many people regain weight after the end of therapy if no lasting changes have been established.
This isn't a weakness, it's biology. The body regulates its weight through complex hormonal feedback mechanisms. GLP-1 therapy suppresses hunger, but it doesn't change the underlying patterns.
Without adjusting eating habits, exercise routines and stress management, lost weight rarely remains stable.
Naturopathic support: Regulation instead of symptom suppression
From a naturopathic perspective, GLP-1 therapy is not an isolated intervention, but rather an intervention in a complex system. This intervention can be beneficial, but it should be accompanied by other medical advice.
Specifically, this means:
Ensure adequate protein intake: 1.2 to 2.0 grams per kilogram of body weight daily. Strategically use high-quality sources such as fish, eggs, legumes, or plant-based proteins.
Check micronutrients: Regularly monitor vitamin B12, iron, zinc, magnesium, vitamin D and omega-3 fatty acids and supplement if necessary.
Integrate strength training: Two to three sessions per week, adapted to individual capacity.
Supporting digestion: Bitter substances, fiber and probiotics can help regulate constipation and bloating.
Pay attention to the stress axis: Weight loss puts a strain on the body. The adrenal glands need support to avoid chronic overload.
Changing eating habits in the long term: GLP-1 therapy can be a bridge. But without a conscious change in patterns, the effect remains temporary.
For whom is GLP-1 therapy beneficial?
Wegovy is approved for people with a BMI over 30 or from BMI 27 with weight-related comorbidities such as high blood pressure, type 2 diabetes or lipid metabolism disorders.
From a naturopathic perspective, the question is not only whether someone meets the criteria, but also whether the person is willing to actively participate in the therapy.
Those who are unwilling to adjust their diet, do strength training, or monitor their nutrient intake will benefit less in the long run. GLP-1 medications are not a passive solution.
Effective, yes, but with responsibility
Wegovy and Ozempic are effective. They reduce weight, improve metabolic parameters, and can be a useful tool for some people.
At the same time, they deeply interfere with regulatory processes. Muscle loss, nutrient deficiencies, and relapse after discontinuation are real risks that should not be ignored.
From a naturopathic perspective, it is crucial that GLP-1 therapy is not understood as a replacement for change, but as support for it.
Anyone hoping that an injection will solve the problem will be disappointed.
My name is Nadia Licci, a certified naturopathic practitioner. In my practice Total Balance in Zurich, I support people in understanding changes in their bodies and enabling sustainable regulation – even during drug therapies.
